China Clears Mepolizumab for COPD

China Clears Mepolizumab for COPD

China clears GSK’s Nucala (mepolizumab) for COPD, highlighting growing acceptance in the country for biomarker-driven therapies.

GSK Secures China Approval for Nucala in Broad COPD Patient Population

GSK Secures China Approval for Nucala in Broad COPD Patient Population (IN BRIEF) GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils. Supported by positive MATINEE and METREX phase III trial data, the approval makes Nucala the first monthly biologic in China studied in a broad COPD population with b…